<DOC>
	<DOCNO>NCT01497119</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy JNJ-39758979 adult Japanese patient moderate , active atopic dermatitis .</brief_summary>
	<brief_title>A Study JNJ-39758979 Adult Japanese Patients With Moderate Atopic Dermatitis</brief_title>
	<detailed_description>This randomize ( treatment assign chance ) , double-blind ( patient investigator know treatment give ) , multicenter , parallel-group , exploratory study adult Japanese patient moderate atopic dermatitis . This study include 3 phase . In screen phase , patient ' eligibility determine . During treatment phase , eligible patient receive JNJ-39758979 , 300 100 mg daily , placebo ( treatment look like JNJ-39758979 , contain active agent ) 6 week . Study visit occur end Weeks 1 , 2 , 4 , 6 . There follow-up visit 4 week dose complete . The duration participation study individual patient may 14 week ( include screen ) . Patient safety monitor throughout study .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Diagnosis atopic dermatitis base criterion Japanese Dermatological Association : pruritus ( itch ) ; eczemalike change typical pattern , chronic chronically relapse course . Childhood onset ( age 13 ) atopic dermatitis . Diagnosis moderate atopic dermatitis base Rajka Langeland score 4.5 7.5 , inclusive . Have least 3 rating `` Moderate itching '' , `` Severe itching '' , `` Extremely severe itch '' either night day base Pruritus Categorical Response Scale ( PCRS ) 7 day prior randomization . Atopic dermatitis 10 % 50 % ( inclusive ) Body Surface Area ( BSA ) involvement . Have current sign symptom liver renal insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance severe , progressive uncontrolled Investigator 's opinion . Patients well control asthma , allergic rhinitis , allergic conjunctivitis allow participate . Atopic dermatitis patient chronic condition exclude Investigator determine condition severe progressive control stable therapy . Have know malignancy history malignancy ( exception basal cell carcinoma , squamous cell carcinoma situ skin , squamous cell carcinoma skin treat evidence recurrence within 5 year prior first administration study agent ) . Evidence skin condition , opinion Investigator , would interfere assessment atopic dermatitis . Use nonsteroid immunosuppressive immunomodulatory agent within 4 week randomization , include cyclosporine A , azathioprine , mycophenolate mofetil , interferon gamma . Use systemic corticosteroid within 4 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Moderate atopic dermatitis</keyword>
	<keyword>JNJ-39758979</keyword>
	<keyword>Japanese patient</keyword>
</DOC>